SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Public ClinicalTrials.gov record NCT04291079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors. The study was divided into 3 treatment parts (Part A1, Part A2, and Part B) and a Long-Term Extension Phase (LTEP).
Study identification
- NCT ID
- NCT04291079
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2020 (Actual)
- Primary completion
- Apr 14, 2025 (Actual)
- Completion
- Apr 14, 2025 (Actual)
- Last update posted
- Apr 29, 2025
2020 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Jude Crosson Cancer Institute | Fullerton | California | 92835 | — |
| University of California - San Diego | La Jolla | California | 92093 | — |
| The Oncology Institute | Los Angeles | California | 90603 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Advent Health | Celebration | Florida | 34747 | — |
| Memorial Cancer Institute - South Broward Hospital District | Hollywood | Florida | 33021 | — |
| H. Lee Moffitt Cancer Center& Research Institute | Tampa | Florida | 33612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne | Indiana | 46804 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02155 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | — |
| Stony Brook University Cancer Center | Stony Brook | New York | 11794 | — |
| Tennessee Oncology, Sarah Cannon Research Institute | Nashville | Tennessee | 37201 | — |
| BUMC Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04291079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04291079 live on ClinicalTrials.gov.